Lynk Pharmaceuticals Announces Completion of Patient Enrollment in Phase III Clinical Trial of Zemprocitinib for Ankylosing Spondylitis
HANGZHOU, China and SHANGHAI and BOSTON, July 15, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune…
Read the full articleYou might also wanna read
Four JAK Inhibitors Show Positive Late-Stage Trial Results for Axial Spondyloarthritis Treatment
Data from phase 3 studies with filgotinib, gecacitinib, and ivarmacitinib and a phase 4 study of tofacitinib in early disease are reported.
mdsc.pe·25d agoBimekizumab well tolerated, efficacious over three years in axial spondyloarthritis
For patients with axial spondyloarthritis (axSpA), bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, is well tolerated over thr
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Conditions : Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus Interventions : Combination Product: Anifrolumab;
Efficacy and Safety of Low-Dose Upadacitinib Combined With Ustekinumab in the Treatment of Refractory Crohn's Disease
Conditions : Inflammatory Bowel Disease (IBD); Crohn's Disease Interventions : Drug: Upadacitinib; Drug: Ustekinumab (UST) Sponsors : Shangh
A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity
Conditions : Obesity; Elevated High-sensitivity C-reactive Protein (hsCRP) Interventions : Drug: NNC6022-0004; Drug: Placebo Sponsors : Novo
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Conditions : Plaque Psoriasis; Metabolic Dysfunction-Associated Steatotic Liver Disease Sponsors : Novartis Pharmaceuticals Not yet recruiti
Comments
Sign in to join the conversation.
No comments yet. Be the first.